

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claim 1. (currently amended) A humanized monoclonal antibody that binds to Shiga toxin protein, comprising a constant region and a murine variable region, wherein said constant region contains at least part of a human immunoglobulin constant region and said murine variable region contains at least part of a murine immunoglobulin variable region as shown in Figure 3 (SEQ ID NO: 21) or Figure 6 (SEQ ID NO: 42), wherein the antibody specifically reacts with Stx1 or Stx2 antigen and further wherein the variable region comprises one of the following heavy chain CDRs: amino acids 31-35 of SEQ ID NO: 44, amino acids 50-66 of SEQ ID NO: 44, amino acids 99-108 of SEQ ID NO: 44 or a modification thereof; and one of the following light chain CDRs: amino acids 24-40 of SEQ ID NO: 42, amino acids 56-62 of SEQ ID NO: 42, amino acids 95-103 of SEQ ID NO: 42 or a modification thereof, wherein the modification does not diminish the specific reaction with the Stx 1 or Stx2 antigen.

Claim 2. (original) The humanized monoclonal antibody of claim 1, having the same binding specificity as the antibody selected from the group consisting of murine 13C4 (ATCC Accession No. CRL 1794), murine 11E10 (ATCC Accession No. CRL 1987), humanized 13C4 (H13C4), and humanized 11E10 (H11E10).

Claims 3-13 (canceled)

Claim 14. (original) The humanized monoclonal antibody of claim 13, wherein said non-human variable region is from a mouse.

Claims 15-16 (canceled)

Claim 17. (original) The humanized monoclonal antibody of claim 13, wherein said human constant region is selected from group consisting of IgG, IgA and IgM.

Claim 18. (original) The humanized monoclonal antibody of claim 17, wherein said human constant region is IgG.

Claim 19. (original) A humanized monoclonal antibody which binds Shiga toxin type 2 and Shiga toxin type 2 variants, comprising a constant region and a variable region, wherein:
said constant region is IgG1-kappa, and
said variable region contains at least part of the sequence as set forth in SEQ ID NO:42 and SEQ ID NO:44.

Claim 20. (currently amended) A humanized monoclonal antibody which binds Shiga toxin type 2 and Shiga toxin type 2 variants, comprising a constant region and a variable region, wherein:

said constant region is IgG1-kappa, and

[said variable region contains at least part of the CDR sequences located as follows:

Heavy Chain CDRs: CDR1-aa31-35

(SEQ ID NO:44) CDR2-aa50-66 CDR3-aa99-108

Light Chain CDRs: CDR1-aa24-40

(SEQ ID NO:42) CDR2-aa56-62 CDR3-aa95-103] wherein the variable region comprises amino acid sequences selected from the group consisting of amino acids 31-35 of SEQ ID NO: 44, amino acids 50-66 of SEQ ID NO: 44, amino acids 99-108 of SEQ ID NO: 44, amino acids 24-40 of SEQ ID NO: 42, amino acids 56-62 of SEQ ID NO: 42, and amino acids 95-103 of SEQ ID NO:42.

Claims 21-22 (canceled)

Claim 23. (currently amended) A [pharmaceutical] composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claims 24-28 (canceled)

Claim 29. (currently amended) A [pharmaceutical] composition comprising the antibody of claim 13 and a pharmaceutically acceptable carrier or diluent.

Claims 30-31 (canceled)

Claim 32. (previously presented) A humanized monoclonal antibody that binds to a Shiga toxin protein comprising a human immunoglobulin constant region and a variable region, wherein the variable region comprises amino acid sequences selected from the group consisting of amino acids 31-35 of SEQ ID NO: 44, amino acids 50-66 of SEQ ID NO: 44, amino acids 99-108 of SEQ ID NO: 44, amino acids 24-40 of SEQ ID NO: 42, amino acids 56-62 of SEQ ID NO: 42, and amino acids 95-103 of SEQ ID NO: 42.

Claim 33. (previously presented) A fragment of the antibody of claim 32 wherein the fragment binds a Shiga toxin protein.

Claim 34. (previously presented) The humanized monoclonal antibody of claim 32 wherein the human constant region is selected from the group consisting of IgG, IgA and IgM.

Claim 35. (previously presented) The humanized monoclonal antibody of claim 32 wherein the human constant region is IgG.

Claim 36. (previously presented) The humanized monoclonal antibody of claim 32 wherein the human constant region is IgG1-kappa.

Claim 37. (previously presented) The humanized monoclonal antibody of claim 32 wherein the variable region comprises the amino acid sequence of SEQ ID NO: 44.

Claim 38. (previously presented) The humanized monoclonal antibody of claim 32 wherein the variable region comprises the amino acid sequence of SEQ ID NO: 42.

Claim 39. (currently amended) A [pharmaceutical] composition comprising an antibody of claim 32 and a pharmaceutically acceptable carrier or diluent.

Claim 40. (currently amended) A [pharmaceutical] composition comprising an antibody fragment of claim 32 and a pharmaceutically acceptable carrier or diluent.

Claim 41. (previously presented) A monoclonal antibody selected from the group consisting of murine 13C4 (ATCC Accession No. CRL 1794), murine 11E10 (ATCC Accession No. CRL 1987), humanized 13C4 (H13C4) and humanized 11E10.

Claim 42. (canceled)

Claim 43. (previously presented) The humanized monoclonal antibody of claim 1, wherein the human immunoglobulin constant region is as shown in Figure 3 (SEQ ID NO: 19) or Figure 6 (SEQ ID NO: 44).